US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold (updated)
15/06/2023 12:58
(Adds details on clinical hold in paragraph 2 and 3)
June 15 (Reuters) - Mersana Therapeutics Inc MRSN.O
said on Thursday the U.S. Food and Drug Administration (FDA) had
put a partial clinical hold on its ovarian cancer drug studies
and paused patient enrollment, citing safety concerns.
Shares of Mersana Therapeutics fell 54.3% to $4.20 in
premarket trading on the news.
The partial clinical hold from the health regulator follows
a submission by Mersana of a recent safety report that showed
five serious bleeding events in patients dosed with its
experimental drug, UpRi, the company said.
The patients who are already enrolled in the studies will
continue to receive the treatment.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Savio
D'Souza and Shinjini Ganguli)
((Khushi.Mandowara@thomsonreuters.com;))